Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
14 mai 2021 09h15 HE
|
Recro Pharma, Inc.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $34.5 Million EXTON, Pa., May 14, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and...
Recro Announces Pricing of $30.0 Million Public Offering of Common Stock
12 mai 2021 08h30 HE
|
Recro Pharma, Inc.
EXTON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Announces Proposed Public Offering of Common Stock
11 mai 2021 16h30 HE
|
Recro Pharma, Inc.
EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Reports First Quarter 2021 Financial Results
06 mai 2021 16h05 HE
|
Recro Pharma, Inc.
Revenues of $16.8 Million Represent an Increase of 70% Compared to Q4 2020 Revenue Multiple New Business Agreements Signed Facilities Expansion and Enhancements Continue Company to Host Conference...
Recro to Report Financial Results for First Quarter 2021 on May 6
29 avr. 2021 16h05 HE
|
Recro Pharma, Inc.
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences
15 avr. 2021 07h00 HE
|
Recro Pharma, Inc.
GAINESVILLE, Ga., April 15, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
Recro Reports Inducement Grants for New Staff
06 avr. 2021 07h00 HE
|
Recro Pharma, Inc.
MALVERN, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Strengthens Business Development Team to Drive Customer Growth and Diversification
05 avr. 2021 07h00 HE
|
Recro Pharma, Inc.
Six Recent Hires Provide Broader Coverage and Expanded Capabilities in the Areas of Sales and Marketing Significant Traction Already Achieved in First Months of 2021 MALVERN, Pa., April 05, 2021 ...
Recro to Present at H.C. Wainwright Global Life Science Conference
02 mars 2021 07h00 HE
|
Recro Pharma, Inc.
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Reports Fourth Quarter and Year End 2020 Financial Results
26 févr. 2021 07h00 HE
|
Recro Pharma, Inc.
Strengthened Industry-Centric Leadership Reorganization Initiated to Enhance Operations as Recro Expands Customer Portfolio, Explores Inorganic Growth Opportunities Core Commercial Product Outlook...